by Cal Strode | Jan 20, 2025
2025 marks the third time I’ve covered the Alliance for Regenerative Medicine (ARM) State of the Industry Briefing for Signals. In 2024’s installation, I noted the strong emphasis on the cell and gene therapy (CGT) industry’s acceleration, driven by scientific...
by Stacey Johnson | Jul 29, 2016
It was Science magazine’s 2013 breakthrough of the year and called a “turning point in cancer.” It even scored its own awareness month that year. Cancer immunotherapy – therapies that harness the power of a patient’s immune system to fight their disease – had...
by Mark Curtis | May 14, 2014
. Welcome to your RM deal review for the month of April. There were two notable acquisitions this past month. NeoStem entered into an agreement to acquire California Stem Cell, while Aastrom acquired Sanofi’s regenerative medicine business. Read on to find out more....
by Mark Curtis | Jan 13, 2014
. Welcome to your Regenerative Medicine Deal Review for the month of December. Toronto-based Stem Cell Therapeutics successfully executed on a financing of $33 million, while Pluristem announces it is moving forward on a licensing agreement with Korea-based CHA....
by Lisa Willemse | Jan 10, 2014
> Earlier this week, we tweeted some articles published online at Scientific American that provide some perspectives on the complexity and high costs of drug discovery – so far, two have been published, here and here. The tweet elicited a thought-provoking...
Comments